Drug discovery firm Syntekabio has entered into a partnership with compound supplier Enamine to advance artificial intelligence (AI)-based synthetic drug development.
The memorandum of understanding (MoU) between the two companies will enhance their collaboration in compound supply, synthesis, and AI-based drug development at Syntekabio’s AI Bio Supercomputer Center (ABS Center) in Daejeon, South Korea.
Under this agreement, Enamine will supply a library of synthetic compounds, which Syntekabio will integrate into its AI drug discovery platform, DeepMatcher.
The collaboration aims to optimise lead compounds for drug development.
Additionally, the partnership will focus on accelerating global market expansion through joint marketing efforts related to AI-driven drug discovery services.
Enamine business development director Iaroslava Kos said: “This partnership aims to accelerate the discovery of optimised lead compounds, enhancing the efficiency and effectiveness of drug development.
“By combining our strengths, we look forward to making significant advancements in the field of synthetic drug development.”
Enamine, headquartered in Kyiv, Ukraine, offers in vitro efficacy verification services, including binding assays and ADMET screening. The company has recently expanded its global presence with new branches in the US, Germany, and Poland.
Through this collaboration, Enamine will apply its expertise in chemical synthesis, custom synthesis, and preclinical biology services to enhance drug optimisation and lead compound discovery, utilising Syntekabio’s advanced AI-based molecular design capabilities.
Syntekabio is also advancing bio-drug research with its NEO-ARS and Ab-ARS platforms, alongside its synthetic drug candidate discovery service via DeepMatcher.
Syntekabio chief scientific officer Hye-Kyung Cho said: “Syntekabio’s main business model is to provide synthetic drug candidate discovery services using DeepMatcher to domestic and international clients, and securing a compound library is the foundation for discovering excellent candidate substances.
“By incorporating Enamine’s large-scale compound library into DeepMatcher through this collaboration, we expect to provide enhanced AI drug services and strengthen our competitiveness in the global market.”
The latest partnership comes after Syntekabio collaborated with bioSeedin, a subsidiary of ACROBiosystems, to promote its AI drug active compound database, STB LaunchPad and other drug discovery technologies.
In January, Enamine partnered with SyntheticGestalt to develop an AI-driven model for drug discovery.
